<DOC>
	<DOCNO>NCT00918281</DOCNO>
	<brief_summary>Study aim assess reproducibility PET image use AH111585 ( 18F ) Injection . Subjects evaluable undergo 2 administration AH111585 ( 18F ) Injection ( 3 8 day apart ) correspond PET acquisition , tumor demonstrate detectable level 18F uptake PET .</brief_summary>
	<brief_title>Reproducibility 18F Uptake Solid Tumors Using PET Imaging Following Intravenous Administration ( 18F ) Injection</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<criteria>The subject diagnose least one solid primary metastatic tumor great 2.0 cm diameter , include limited NSCLC , RCC , GBM , melanoma , sarcoma , breast H &amp; N cancer . The subject receive clinical routine imaging diagnostic workup within 8 week prior first [ 18F ] AH111585 PET scan . The subject clinically acceptable ( judged investigator ) physical examination screen capable selfcare . The subject know hyper hypocoagulation syndrome . The subject receive chemotherapy within 3 week , receive radiotherapy , surgery treatment cancer within 4 week prior first [ 18F ] AH111585 PET scan . The subject schedule undergo chemotherapy , radiotherapy , surgery treatment cancer first second [ 18F ] AH111585 PET scan . The subject schedule undergo biopsy target tumour first second [ 18F ] AH111585 PET scan . The subject intrahepatic tumour ( ) . For immunohistochemistry group , subject 's target tumour biopsied less equal 1 week prior first [ 18F ] AH111585 PET scan .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>